Charles Schwab’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-201,352
| Closed | -$1.89M | – | 3429 |
|
|
2020
Q3 | $1.89M | Sell |
201,352
-15,567
| -7% | -$148K | ﹤0.01% | 2510 |
|
|
2020
Q2 | $1.66M | Buy |
216,919
+7,473
| +4% | +$57.2K | ﹤0.01% | 2476 |
|
|
2020
Q1 | $1.29M | Buy |
209,446
+3,932
| +2% | +$34.6K | ﹤0.01% | 2427 |
|
|
2019
Q4 | $2.5M | Buy |
205,514
+4,319
| +2% | +$47.2K | ﹤0.01% | 2353 |
|
|
2019
Q3 | $2.32M | Sell |
201,195
-54,314
| -21% | -$572K | ﹤0.01% | 2337 |
|
|
2019
Q2 | $2.55M | Sell |
255,509
-73,758
| -22% | -$796K | ﹤0.01% | 2286 |
|
|
2019
Q1 | $4.24M | Sell |
329,267
-70,411
| -18% | -$1.05M | ﹤0.01% | 2050 |
|
|
2018
Q4 | $6.07M | Sell |
399,678
-26,746
| -6% | -$510K | ﹤0.01% | 1790 |
|
|
2018
Q3 | $8.53M | Buy |
426,424
+18,960
| +5% | +$432K | 0.01% | 1742 |
|
|
2018
Q2 | $7.95M | Buy |
407,464
+34,833
| +9% | +$771K | 0.01% | 1745 |
|
|
2018
Q1 | $7.51M | Sell |
372,631
-74,732
| -17% | -$1.26M | 0.01% | 1692 |
|
|
2017
Q4 | $5.93M | Buy |
447,363
+22,488
| +5% | +$339K | ﹤0.01% | 1832 |
|
|
2017
Q3 | $7.84M | Buy |
424,875
+134,080
| +46% | +$2.5M | 0.01% | 1617 |
|
|
2017
Q2 | $5.35M | Sell |
290,795
-11,973
| -4% | -$237K | 0.01% | 1776 |
|
|
2017
Q1 | $6.83M | Sell |
302,768
-131,459
| -30% | -$3.15M | 0.01% | 1577 |
|
|
2016
Q4 | $15.1M | Buy |
434,227
+7,528
| +2% | +$225K | 0.02% | 950 |
|
|
2016
Q3 | $10.5M | Buy |
426,699
+19,478
| +5% | +$487K | 0.01% | 1140 |
|
|
2016
Q2 | $9.74M | Buy |
407,221
+1,892
| +0.5% | +$43.4K | 0.01% | 1090 |
|
|
2016
Q1 | $9.48M | Sell |
405,329
-19,875
| -5% | -$472K | 0.01% | 1084 |
|
|
2015
Q4 | $12.8M | Buy |
425,204
+16,870
| +4% | +$545K | 0.02% | 864 |
|
|
2015
Q3 | $16.2M | Buy |
408,334
+156,154
| +62% | +$9.69M | 0.02% | 651 |
|
|
2015
Q2 | $17.4M | Buy |
252,180
+165,645
| +191% | +$10.4M | 0.02% | 637 |
|
|
2015
Q1 | $4.73M | Buy |
86,535
+30,254
| +54% | +$1.44M | 0.01% | 1549 |
|
|
2014
Q4 | $2.4M | Sell |
56,281
-72,648
| -56% | -$2.62M | ﹤0.01% | 1910 |
|
|
2014
Q3 | $4.12M | Sell |
128,929
-9,239
| -7% | -$197K | 0.01% | 1539 |
|
|
2014
Q2 | $2.86M | Sell |
138,168
-400
| -0.3% | -$7.39K | ﹤0.01% | 1773 |
|
|
2014
Q1 | $2.68M | Sell |
138,568
-76,870
| -36% | -$1.63M | ﹤0.01% | 1785 |
|
|
2013
Q4 | $5.23M | Sell |
215,438
-20,810
| -9% | -$489K | 0.01% | 1222 |
|
|
2013
Q3 | $5.16M | Sell |
236,248
-21,765
| -8% | -$514K | 0.01% | 1155 |
|
|
2013
Q2 | $5.77M | Buy |
+258,013
| New | +$5.69M | 0.01% | 930 |
|
Charles Schwab's AMAG Position: Q4 2020 in Review
Charles Schwab sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 201,352 shares — an estimated $1.89M sold.
Charles Schwab first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $17.4M in Q2 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Charles Schwab reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Charles Schwab sold 201,352 AMAG Pharmaceuticals shares in Q4 2020, an estimated $1.89M.
- Charles Schwab first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Charles Schwab's AMAG Pharmaceuticals position peaked at $17.4M in Q2 2015.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Charles Schwab's 13F filing for Q4 2020, filed 16 Feb 2021.